RSV Prophylaxis Update
Due to current supply constraints for the new RSV prophylaxis agent Beyfortus (nirsevimab), the MO HealthNet Division (MHD) will allow up to five doses of Synagis (palivizumab) for the 2023 – 2024 RSV season. Participants who meet the clinical edit requirements, including age restrictions, may receive approval for up to five doses to start the 2023 - 2024 RSV season, depending on the requested date for the initial prior authorization.
